Skip to content

Impact of Nicotine on Retinal Vascularization

Impact of Nicotine on Retinal Vascularization (Tabaret)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03964623
Acronym
TABARET
Enrollment
58
Registered
2019-05-28
Start date
2019-07-17
Completion date
2022-12-02
Last updated
2023-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tabagism

Keywords

OCT-A, smokers, vapers, non-smokers/non-vapers, nicotine, retinal micro-vascularization

Brief summary

The main hypothesis is the nicotine is associated with a modification of retinal micro-vascularization. Patients will be recruited during their ophthalmologic consultation at the Rothschild Foundation, an OCT-A will be realized and data relating to medical history, oral contraceptive intake and nicotine consumption via cigarette or e-cigarette data will be collected. The objective is to seek an association between retinal vascular density and inhaled nicotine intake.

Interventions

Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* For group of smokers: Patient reporting active smoking for at least 3 months and at least 1 cigarette per day on average over a week * For group of vapers : Patient using exclusively the electronic cigarette with a nicotine level of more than 6mg/ml for at least 3 months and at least 1 times per day on average over a week. * For group of no-smokers no-vapersNon-smoking and no vaping, for more than 6 months Non-inclusion criteria: * Caffeine intake within 2 hours prior to the OCT-A exam * ametropia greater than + 3 dioptres of hyperopia or-3 dioptres of myopia * astigmatism greater than 2 dioptres * Known retinal or retina vascular pathology

Design outcomes

Primary

MeasureTime frame
Density of retinal vascular Plexus (quantitative variable expressed as a percentage) using OCT-A.At the inclusion consultation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026